EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.

On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Samsung Bioepis Co Ltd, a biopharmaceutical company committed to realizing healthcare that is accessible to everyone, has announced that the phase 1 study on SB27, a proposed biosimilar to Keytruda ...

Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

At ASCO 2026, AstraZeneca will release the first results from its first-in-human, open-label Phase I/II trial, PRIMAVERA (NCT06137144).

Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.

Dr Hilary Jones has praised a new NHS injection that not only takes 60 seconds to administer but is also set to help tens of ...